144 related articles for article (PubMed ID: 29087153)
1. [[GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE – HOW TO CHOOSE HYPOGLYCEMIC AGENT]?].
Baretić M; Lang VB
Acta Med Croatica; 2016 Dec; 70(4-5):269-74. PubMed ID: 29087153
[TBL] [Abstract][Full Text] [Related]
2. Glycemic management in ESRD and earlier stages of CKD.
Williams ME; Garg R
Am J Kidney Dis; 2014 Feb; 63(2 Suppl 2):S22-38. PubMed ID: 24461727
[TBL] [Abstract][Full Text] [Related]
3. Diabetes management in the kidney patient.
Garg R; Williams ME
Med Clin North Am; 2013 Jan; 97(1):135-56. PubMed ID: 23290735
[TBL] [Abstract][Full Text] [Related]
4. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control.
Betônico CC; Titan SM; Correa-Giannella ML; Nery M; Queiroz M
Clinics (Sao Paulo); 2016 Jan; 71(1):47-53. PubMed ID: 26872083
[TBL] [Abstract][Full Text] [Related]
5. Achieving glycemic control in patients with type 2 diabetes and renal impairment.
Avogaro A; Schernthaner G
Acta Diabetol; 2013 Jun; 50(3):283-91. PubMed ID: 23212669
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of diabetes mellitus in patients with chronic kidney disease].
Bojunga J; Mondorf A
Dtsch Med Wochenschr; 2019 Aug; 144(15):1044-1050. PubMed ID: 31350746
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Abe M; Okada K; Soma M
Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
[TBL] [Abstract][Full Text] [Related]
8. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
9. Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) Study.
Balkau B; Metzger M; Andreelli F; Frimat L; Speyer E; Combe C; Laville M; Jacquelinet C; Briançon S; Ayav C; Massy Z; Pisoni RL; Stengel B; Fouque D
Diabetes Metab; 2019 Apr; 45(2):175-183. PubMed ID: 29706470
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
11. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
Min T; Davies GI; Rice S; Chess J; Stephens JW
Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapy in chronic kidney disease.
Pinelli NR; Moore CL; Tomasello S
Adv Chronic Kidney Dis; 2010 Sep; 17(5):439-49. PubMed ID: 20727514
[TBL] [Abstract][Full Text] [Related]
14. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran H; Cherney DZ; Lovshin JA
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica].
Gómez-Huelgas R; Martínez-Castelao A; Artola S; Górriz JL; Menéndez E;
Med Clin (Barc); 2014 Jan; 142(2):85.e1-10. PubMed ID: 24268912
[TBL] [Abstract][Full Text] [Related]
16. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease.
Nogueira C; Souto SB; Vinha E; Braga DC; Carvalho D
Hormones (Athens); 2013; 12(4):483-94. PubMed ID: 24457396
[TBL] [Abstract][Full Text] [Related]
17. Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes.
Rahhal MN; Gharaibeh NE; Rahimi L; Ismail-Beigi F
J Clin Endocrinol Metab; 2019 Nov; 104(11):4949-4966. PubMed ID: 31162534
[TBL] [Abstract][Full Text] [Related]
18. Management of diabetes in patients with chronic kidney disease.
Ahmed Z; Simon B; Choudhury D
Postgrad Med; 2009 May; 121(3):52-60. PubMed ID: 19491540
[TBL] [Abstract][Full Text] [Related]
19. Glycemic control and burnt-out diabetes in ESRD.
Kovesdy CP; Park JC; Kalantar-Zadeh K
Semin Dial; 2010; 23(2):148-56. PubMed ID: 20374552
[TBL] [Abstract][Full Text] [Related]
20. Glycemic control in diabetic CKD patients: where do we stand?
Kovesdy CP; Sharma K; Kalantar-Zadeh K
Am J Kidney Dis; 2008 Oct; 52(4):766-77. PubMed ID: 18572289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
